MHRA approves Veoza (fezolinetant) to treat vasomotor symptoms associated with menopause – Astellas

Veoza (Veozah in the US), also known as fezolinetant, from Astellas, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) after receiving similar approval in the US back in May 2023.

Menopausal hot flushes are experienced by up to 80% of women going through menopause, and can vary from a few seconds of feeling overheated to significant sweating and discomfort that can disrupt sleep or affect their ability to work, especially for women working in thermal environments. Veoza works by blocking a protein in the brain called neurokinin-3, which plays an important role in regulating body temperature in menopausal women.